Newsroom | 87285 results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration (FDA) issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy (Duchenne) patient who had received ELEVIDYS (delandistrogene moxeparvovec) gene therapy. The death of this patient was deemed unrela...

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company’s Compensation Committee, as material inducements to three individuals whose employment commenced in June 2025. The grants resulted in the right to purchase 52,500 shares of the Company’s common stock and...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that four abstracts highlighting clinical progress across its botensilimab and balstilimab immunotherapy programs have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025, taking place in Berlin, Germany from October 17-21. The highlight is an oral presentation that will feature emerging survival plateaus from a study of botensilimab plus balst...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Provides Regulatory Update on Elinzanetant for the Treatment of Moderate to Severe Hot Flashes Due to Menopause...

DUBLIN--(BUSINESS WIRE)--The "Cardiac Amyloidosis Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The global cardiac amyloidosis market is experiencing substantial growth, driven by the increasing prevalence of amyloidosis-related cardiac conditions and the rising awareness among healthcare professionals and patients. Cardiac amyloidosis, characterized by the abnormal...

DUBLIN--(BUSINESS WIRE)--The "Adult-onset Still Disease Market: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. Adult-onset still disease is a rare, systemic inflammatory disorder characterized by high spiking fevers, salmon-colored rashes, and arthritis. It primarily affects adults and is associated with an overactive immune response. Adult-onset still disease can lead to joint destruction, organ damage, and...

DUBLIN--(BUSINESS WIRE)--The "Pertussis Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The global pertussis market includes various vaccine formulations such as whole-cell vaccines and acellular vaccines, which are used in pediatric and adult immunization schedules. These vaccines are being continually improved for safety, efficacy, and patient acceptance. Acellular v...

DUBLIN--(BUSINESS WIRE)--The "Fabry Disease Market (By Treatment, Route of Administration, Product, End-User, Country Analysis), Key Company Profiles, Product Portfolio, Pipeline Product Analysis, Recent Developments and Market Dynamics - Global Forecast (2025 - 2030)" report has been added to ResearchAndMarkets.com's offering. The global Fabry disease treatment market was valued at US$ 2.22 Billion in 2024, and is predicted to reach US$ 3.86 Billion by 2030. The primary goal of Fabry disease t...

SALT LAKE CITY--(BUSINESS WIRE)--BetterRX, the leading hospice pharmacy platform, today announced a strategic growth investment from BVP Forge, to accelerate its future growth. BetterRX also announced the appointment of Tim Tannert as its new CEO. The investment will support BetterRX’s mission to end needless suffering caused by medication delays by expanding its platform reach, accelerating innovation, and advancing the standard of care in hospice medication management. Purpose-built for hospi...

NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain--(BUSINESS WIRE)--Prilenia Therapeutics B.V. and Ferrer today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the refusal of the marketing authorization for pridopidine’s marketing authorization application for Huntington’s disease (HD). We are disappointed, but undeterred in our commitment to bring what we believe is an effective therapy to patients and will explo...